Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Vetigenics is seeing encouraging results of a completed study for an antibody aimed at treating oral melanoma in dogs, used ...